Subclinical Cushing's syndrome (SCS), a subtle cortisol hypersecretion from an adrenal tumor, may be a common adrenal disease. However, the cardiovascular prognosis and the optimal surgical and conservative treatment in SCS remain elusive. The present study was undertaken to evaluate the prevalence of cardiovascular risk factors in 16 SCS cases, their relationships to cortisol secretory activities, and the clinical outcome after surgical and medical treatment. The prevalence of hypertension, impaired glucose tolerance (IGT), diabetes mellitus (DM), dyslipidemia and obesity in our SCS cases were 56%, 50%, 50%, and 19%, respectively, and 75% of cases were associated with two or more cardiovascular risk factors. In our series, 24-h urinary free-cortisol excretion showed a significant positive correlation with HbA1c and a negative correlation with high-density lipoprotein-cholesterol, but no correlation with age, body mass index, blood pressure or glycemic and lipid profile was found. Eight cases underwent unilateral adrenalectomy (operated (OP) group); the remaining eight cases were a conservative-treatment group (non-OP group). The number of cardiovascular risk factors decreased significantly in the OP group, but not in the non-OP group. In terms of differential changes in risk factors between the groups, more significant improvements of hypertension, dyslipidemia and IGT/DM were observed in the OP group than in the non-OP group. In conclusion, the present study showed the increased prevalence of cardiovascular risk factors in SCS patients with mild hypercortisolism related to impaired glucose/lipid metabolism. Adrenalectomy decreased accumulated cardiovascular risk factors in certain SCS patients, suggesting the possible involvement of mild hypercortisolism in the development of cardiovascular risk factors in SCS.
INTRODUCTION
The term subclinical Cushing's syndrome (SCS) is commonly used to define a condition characterized by subtle cortisol hypersecretion from an adrenal tumor without signs or symptoms of overt Cushing's syndrome (CS). 1 SCS accounts for B5-20% of incidentally discovered adrenal masses (adrenal incidentalomas). 2, 3 Given that 4% of subjects older than 60 years of age harbor such adrenal tumors, SCS is considered a potentially common adrenal disease. 4, 5 It has been shown that SCS is associated with insulin resistance, hypertension, obesity, dyslipidemia, impaired glucose tolerance (IGT) and diabetes mellitus (DM) as frequently as is overt CS. [6] [7] [8] Although it has been well recognized that overt CS patients have a higher rate of mortality due to cardiovascular complications, such as myocardial infarction, congestive heart failure and stroke, 9,10 the cardiovascular prognosis of SCS remains undetermined. Several previous studies have shown the improvement of hypertension after surgical treatment in SCS; 8, [11] [12] [13] however, the outcome of other cardiovascular risk factors, such as diabetes, dyslipidemia and obesity, remains obscure. Because there have been no large studies on the cardiovascular prognosis in SCS, the clinical outcome achieved by surgical and medical management of SCS after long-term follow-up is open to debate. 14 To address the issue, the present retrospective study was undertaken to evaluate the prevalence of cardiovascular risk factors in 16 patients with SCS, their relationships to cortisol secretory activity, and the associated clinical outcomes after surgical and medical treatment.
METHODS

Study population
In all, 16 of 168 patients with adrenal tumors (9.5%) who were diagnosed as SCS at Tokyo Medical and Dental University Hospital during 2002-2008 were retrospectively studied. This study was approved by the Ethics Committee of our institute. Informed consent was obtained from each patient.
The diagnosis of SCS was made on the basis of the diagnostic criteria proposed by the Research Committee for Adrenal Diseases provided by the Japanese Ministry of Health, Labor and Welfare. 15 These criteria include the presence of adrenal incidentaloma, the lack of Cushingoid features and normal basal serum cortisol levels with no suppression by an overnight low-dose (43 mg dl À1 with 1 mg) and a high-dose (41 mg dl À1 with 8 mg) dexamethasone suppression test, and at least one of the following additional endocrine abnormalities: (1) suppressed plasma adrenocorticotropic hormone (ACTH) (o10 pg ml À1 ) and/or decreased response to corticotropin-releasing hormone (CRH) stimulation (o150% increase compared with baseline), (2) loss of cortisol diurnal rhythm (45 mg dl À1 at midnight), decreased serum dehydroepiandrosterone sulfate levels (less than age-and sex-matched reference values), and (4) unilateral radioactive uptake, as determined by adrenal scintigraphy.
Surgical treatment is recommended for the patients with multiple (two or more) cardiovascular risk factors and/or those who desire and agree to undergo surgery, whereas medical treatment is recommended for the patients who are unwilling to undergo surgery regardless of the presence or the absence of cardiovascular risk factors.
Cardiovascular risk factors
Hypertension is defined as diastolic blood pressure 490 mm Hg and/or systolic blood pressure 4140 mm Hg; 16 17 and dyslipidemia as triglyceride (TG) X150 mg dl À1 , high-density lipoprotein-cholesterol (HDL-C) o40 mg dl À1 , or low-density lipoprotein-cholesterol (LDL-C) X140 mg dl À1 . 18 Patients on medication for hypertension, type 2 DM and dyslipidemia were included as having the respective risk factors.
Follow-up study
Eight patients underwent surgical adrenalectomy (the operated (OP) group consisted of six patients with multiple cardiovascular risk factors and two patients who desired surgical treatment), whereas the remaining eight patients were treated with conservative management (non-OP group). Blood pressure (systolic, diastolic), glycemic profile (FPG, immunoreactive insulin (IRI), homeostasis model assessment insulin resistance index, HbA1c, 75 g OGTT), lipid profile (TG, HDL-C, LDL-C) and obesity (body mass index) were evaluated before and after surgery in the OP group. The follow-up period was 28±7 months and 40±19 months for the OP and non-OP groups, respectively.
Clinical outcome
Changes in blood pressure, body weight, and the glycemic and lipid profiles during the follow-up period were evaluated as improved, unchanged or deteriorated. Improvement of hypertension is defined as normalized blood pressure (systolic blood pressure o140 mm Hg and diastolic blood pressure o90 mm Hg) and discontinuation or reduction of the use of anti-hypertensive drugs (number or dose). Deterioration was defined as aggravated hypertension (systolic blood pressure 4140 mm Hg and/or diastolic blood pressure 490 mm Hg) and/or increased dose or number of anti-hypertensive drugs, respectively. Improvement of IGT/DM was defined as normoglycemia/IGT on OGTT, 40.3% decrease in HbA1c levels or discontinuation/decrease in the number or dose of insulin/oral hypoglycemic agents. Deterioration was defined as the development of IGT/DM on OGTT, a 40.3% increase in HbA1c levels, or initiation or increase in the dose of insulin/oral hypoglycemic agents treatment. 12 Improvement of dyslipidemia was defined as normalized plasma lipid levels (TG o150 mg dl À1 , HDL-C X40 mg dl À1 and LDL-C o140 mg dl À1 ) or discontinuation or decrease in the number or dose of anti-dyslipidemia drugs). Deterioration was defined as aggravated dyslipidemia (TG X150 mg dl À1 , HDL-C o40 mg dl À1 and/or LDL-C X140 mg dl À1 ) or initiation or increase in the dose of anti-dyslipidemia drug treatment. Improvement and deterioration of obesity were defined as a 43 kg decrease or increase, respectively, in body weight compared with baseline. 12 A lack of 'improvement' or 'deterioration' of cardiovascular risk factors was defined as 'unchanged.'
Hormonal measurements
Blood samples were withdrawn on the morning after overnight fasting. Plasma ACTH and serum cortisol were measured by immunoradiometric assay (ACTH IRMA Mitsubishi, Mitsubishi Chemical, Tokyo, Japan) and competitive enzyme immunoassay (ST AIA-PACK CORT, Tosoh, Tokyo, Japan), respectively. The serum dehydroepiandrosterone sulfate level was measured by conventional radioimmunoassay.
Statistical analysis
Data are expressed as the means ± s.d. or median (interquartile range of 25-75%), depending on the distribution of data. A log transformation was performed for variables that did not follow a normal distribution. The w 2 test was used to compare proportions of subjects in the two groups. Between-group comparisons were performed using the non-paired t-test. The relationship between two continuous variables was evaluated using Pearson's correlation coefficient. Pre-and post-treatment differences were analyzed using Wilcoxon's signed-rank test. P-values o0.05 were considered significant. All statistical analyses were performed using Windows software Prism 5.0 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Clinical characteristics of 16 patients with SCS are shown in Table 1 . Eight patients underwent unilateral adrenalectomy (OP group), and the remaining eight patients received conservative treatment (non-OP group). Gender, age and the prevalence of cardiovascular risk factors, including hypertension (56%), DM/IGT (25%), dyslipidemia (50%) and obesity (19%), were evaluated. Fasting insulin, homeostasis model assessment insulin resistance index, serum cortisol levels, plasma ACTH levels and 24-h urinary free-cortisol (UFC) excretion were comparable between both groups, although HbA1c and serum dehydroepiandrosterone sulfate levels were significantly (Po0.05) higher and lower in the OP group than in the non-OP group, respectively. Tumor sizes (26.3±8.7 mm) were similar between the two groups.
To determine whether hypercortisolism is related to cardiovascular risk factors, univariate analysis of the relationship between cortisol secretion and various clinical factors was performed. Twenty-fourhour UFC excretion at diagnosis showed a significant (Po0.05) positive correlation with HbA1c (r¼0.63), a negative correlation with HDL-C (r¼À0.56) and a negative, although insignificant, correlation with FPG (r¼0.49, P¼0.073) (Figure 1 ), but no correlation with age, body mass index, blood pressure (systolic, diastolic), LDL-C, TG, FPG, IRI or homeostasis model assessment insulin resistance index (Table 2 ) was found. There were no significant correlations of morning, midnight or post-1 mg dexamethasone suppression test cortisol levels with any of the clinical parameters (data not shown).
To examine whether surgical or medical treatment affects cardiovascular risk factors, changes in the number of risk factors during the follow-up period were compared between the OP and non-OP groups. The number of cardiovascular risk factors tended to increase, although this trend was insignificant (P¼0.096, from 2[0. To further determine which cardiovascular risk factor(s) are responsible for the decreased number of risk factors, changes in clinical outcome (hypertension, dyslipidemia, IGT/DM and obesity) during the follow-up period were compared between the non-OP and OP groups. Significant improvements in hypertension (P¼0.005), dyslipidemia (P¼0.044) and IGT/DM (P¼0.025), but not obesity (P¼0.085), were observed in the OP group compared with the non-OP group (Figure 3) .
DISCUSSION
The present study clearly showed a high prevalence of cardiovascular risk factors and significant correlations of 24-h UFC excretions with HbA1c and HDL-C levels in our SCS patients. The present study further revealed the number of cardiovascular risk factors in SCS patients significantly decreased with improvements in hypertension, dyslipidemia and IGT/DM in the OP group but not in the non-OP group.
The prevalence of IGT/DM (50%) in our SCS patients (male: 29%, female: 21%) was higher than in the general Japanese population (50-59 y.o), whereas the prevalence of hypertension (56%) and obesity (19%) in our series was comparable with that in the general population in Japan: hypertension, 51% among males and 41% among females; and obesity, 31% among males and 21% among females. 19 Notably, 75% of our SCS patients exhibited two or more cardiovascular risk factors, suggesting the accumulation of cardiovascular risk factors in SCS. Our data are in agreement with those of previous studies, [6] [7] [8] 11, 20, 21 as well as a recent report from Japan. 12 Taken together, these data suggest that even a mild cortisol excess in SCS could have a crucial role in the accumulation of cardiovascular risk factors. Plasma ACTH (pg ml À1 ; reference range: 10-60) 9.1 ± 4.9 9.3 ± 5. The present study clearly demonstrated that 24-h UFC excretion, a reliable index of daily cortisol production, positively correlated with HbA1c levels and negatively with HDL-C levels in our SCS patients. Because chronic glucocorticoid excess is associated with insulin resistance 22 and decreased HDL-C levels 23, 24 in overt CS patients, it is suggested that even the mild cortisol excess in SCS could contribute to impaired glucose and lipid metabolism. In agreement with a previous study, 12 midnight cortisol and post-dexamethasone suppression test cortisol levels (both indices of autonomous cortisol secretion) did not correlate with any of the clinical parameters in our SCS patients. We have recently shown that excessive rather than autonomous cortisol secretion is more closely associated with endothelial dysfunction, an early stage of atherosclerosis, in overt CS patients. This condition is reversible after correction of hypercortisolemia. 25 Thus, a mild excess of cortisol secretion, as reflected by 24-h UFC excretion, is likely to affect glycemic and lipid metabolism in SCS patients. It is therefore suggested that SCS patients with higher UFC excretion represent potential candidates for surgical treatment. However, because of the limited number of patients included in our series, the extent to which UFC excretion is causally related to abnormal glycemic and lipid metabolism in SCS patients remains to be determined.
In the present study, the number of cardiovascular risk factors significantly decreased in SCS patients treated with adrenalectomy but not in patients subjected to conservative treatment. Our data complement those reported by other studies. 12, 13 Thus, surgical treatment could be beneficial among SCS patients, serving to improve cardiovascular morbidity and/or mortality by decreasing the cardiovascular risk factors possibly resulting from correction of a mild cortisol excess.
It remains controversial whether cardiovascular risk factors in SCS patients could improve after adrenalectomy. Several studies have reported that hypertension improved after adrenalectomy in SCS patients, 8, [11] [12] [13] whereas some studies have shown that adrenalectomy did not significantly improve the CVD risk profile. 26, 27 The present study, however, showed that not only hypertension but also DM/IGT and dyslipidemia significantly improved in our SCS patients after the removal of adrenal tumors. Our data are in accordance with those of a recent study showing that blood pressure, weight and fasting glucose in SCS patients improved after adrenalectomy. 28 These findings lend strong support to the contention that surgical removal of adrenal tumors could be a therapeutic option for SCS patients who present with multiple cardiovascular risk factors, such as hypertension, IGT/ DM and dyslipidemia. However, larger prospective clinical studies are required to address the key issue, that is, whether surgical treatment can reduce cardiovascular morbidity and mortality in SCS patients over the long term.
The present study carries certain limitations. First, because of the retrospective nature of the study, we could not match the baseline characteristics of the non-OP group and the OP group with higher HbA1c and lower dehydroepiandrosterone sulfate levels. Second, because we could not standardize the treatment regimes for hypertension, diabetes and dyslipidemia, it is difficult to differentiate the influence of surgical intervention from the effects of various treatments involving lifestyle modifications, such as diet and exercise, medications and patient compliance. Third, because of the limited number of SCS patients, we could not perform multivariate analysis to identify any independent determinant(s) of indication and outcome of treatment. A prospective study with a larger sample size is required.
In conclusion, the present study demonstrated the increased prevalence of cardiovascular risk factors among SCS patients as well as a positive correlation between mild hypercortisolism and impaired glucose/lipid metabolism. Adrenalectomy significantly improved hypertension, dyslipidemia and diabetes/IGT in SCS patients, suggesting the possible involvement of mild hypercortisolism in the development of multiple cardiovascular risk factors in SCS. 
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